BEIJING & ALAMEDA, Calif. & TAIPEI — Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking ...

WUXI BIO (02269.HK) announced that it had inked a research service collaboration agreement with Candid Therapeutics. Under ...

Under the terms of the license agreement, Immunome will be responsible for the research, development, manufacturing and ...

I-Mab said it has paused the development of uliledlimab to focus on a Phase I trial of its lead candidate givastomig.

Monoclonal Antibodies IndustryThe global monoclonal antibodies (mAbs) industry, valued at USD 186 billion in 2021, is ...

After hours: January 3 at 7:49:01 PM EST Loading Chart for IPA ...

Ibio Inc. has expanded its cardiometabolic and obesity treatment development program by in-licensing a long-acting anti-myostatin antibody from Astralbio Inc. The antibody, now named IBIO-600, was ...

Naya Biosciences Inc. has expanded its bifunctional antibody pipeline to include NY-500, a novel PD-1 x VEGF tetravalent bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) and ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications• NAYA aiming to ...

and Teva – along with Amazon Web Services, Inc. (AWS) and the Israel Biotech Fund (IBF) have also launched AION labs, an incubator to accelerate AI-driven antibody discovery. Biopharma companies ...

WuXi Biologics has signed a deal with Sino Biopharm to develop a first-in-class monoclonal antibody targeting an undisclosed ...